Status: Recruiting
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).
Participants needed: 256
Trial details
Phase: Phase 2Age: 16+Biological sex: AllType: InterventionalSponsor: Calmy AlexandraUpdated: Feb 18, 2026Locations: 4
Eligibility criteria
Laboratory confirmed SARS-CoV-2 infection by real time RT-PCR or positive antige... [+26]
SARS-CoV-2 PCR ≥30 CT at screening [+9]